FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for EXJADE (deferasirox) from Novartis Pharmaceuticals Corporation, related to its iron chelation indication for chr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Overload Due to Blood Transfusions

Drugs mentioned

• Exjade (deferasirox)

Snippet

SUPPL AP for EXJADE (DEFERASIROX)